Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in advanced non–small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply best practices for molecular testing to identify actionable mutations in clinical practice
• Evaluate recent data on current and emerging targeted therapies for advanced NSCLC
• Incorporate molecular testing results alongside patient- and disease-specific characteristics to design personalized treatment plans for advanced NSCLC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AbbVie Inc, Lilly, and Partner Therapeutics.

Chair:

Narjust Florez, MD, FASCO

Associate Director, Cancer Care Equity Program
Co-Director, Young Lung Cancer Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Bristol Myers Squibb, Caris Life Sciences, Catalyst Pharmaceuticals, Daiichi Sankyo, EMD Serono, Genentech, Jazz Pharmaceuticals, Johnson & Johnson, Lilly, Merck, Mirati Therapeutics, Novartis, Nuvalent, Nuvation Bio, Pfizer, Regeneron, Sanofi, Takeda Pharmaceuticals; Speakers Bureau: ASCO Post, Clinical Care Options, CME Outfitters, DAVA Oncology; Grant/Research Funding: American Society of Clinical Oncology, AstraZeneca, Champa Fund for Early Cancer Detection, Daiichi Sankyo, Genentech, GO2 for Lung Cancer, International Association for the Study of Lung Cancer, Johnson & Johnson, LUNGevity Foundation, Pfizer, Women’s Health Access Matters Foundation

Faculty:

David P. Carbone, MD, PhD

Professor
Department of Internal Medicine
Director
Thoracic Oncology Center
The Ohio State University Comprehensive Cancer Center
Columbus, OH

Disclosures: Advisory Boards: AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo, DAVA, EMD Serono, Gilead, Iovance, Janssen Global Services, LLC, Johnson & Johnson, Lilly, Lumanity, Merck, Merck KGaA, Natera, OncoHost, Pfizer, Regeneron, Roche, Synthekine Inc., Taiho Oncology, Tempus, Veracyte

Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, CA

Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, ArriVent BioPharma, AstraZeneca, Bayer, Bicycle Therapeutics, Black Diamond Therapeutics, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, GlaxoSmithKline, I-Mab, Hexagon, iTeos, LianBio, Merck, Novartis, Nuvalent, Oxford Bio, Pfizer, Regeneron, Samsung, Sanofi, Servier, Strata, Synthekine, TransCode, Verastem; Grant/Research Funding: ABL Bio, ArriVent BioPharma, AstraZeneca, Bayer, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, Gilead Sciences, Iovance Biotherapeutics, Merck, Novartis, Prelude, Regeneron, Synthekine, TILT Biotherapeutics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including panel discussion and audience Q&A, go to https://www.gotoper.com/ltb26nsclc-activity.

Release Date

March 27, 2026

Expiration Date

March 27, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.